Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: ReNeuron Plans Fundraise To Support Study

Mon, 23rd Nov 2020 19:09

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

ReNeuron Group PLC - Bridgend, Wales-based cell-based therapeutics - Intends to raise gross proceeds up to GBP13.9 million via placing with institutional and other investors alongside up to GBP1.1 million direct subscription. Both will be priced at 70 pence per share with proceeds allowing ReNeuron "to deliver extended clinical data from its ongoing retinitis pigmentosa phase 2a study and to deliver proof-of-concept pre-clinical data from ongoing exosome collaborations which could enable potential out-licensing deals, as detailed below more fully." Also announces up to GBP2. million open offer.

----------

Lekoil Ltd - African oil exploration and production firm with interests in Nigeria and offshore Namibia - Announces that 15.4% stakeholder Lynchwood Nominees Ltd has requisitioned an extraordinary general meeting where it seeks to oust Chair Mark Simmonds and appoint Michael Ajukwu, Thomas Richardson and George Maxwell to the Lekoil board. Requisition further proposes special resolutions relating to restriction to bee place on the affairs of Lekoil Ltd (Nigeria), Lekoil's principal subsidiary. Leoil in "advanced talks" with new nominated advisor, who will review resolutions proposed. This is expected to extend the due diligence process needed before new nomad is appointed, increasing the risk of share delisting.

----------

Versarien PLC - Cheltenham-based advanced materials engineer - Announces interim results reporting extension and will now release its interim results for the six months ended September 30 by January 31 at the latest. This is in line with Covid-19 guidance allowing for a 1-month extension for reporting interim financial results.

----------

Martin Currie Global Portfolio Trust PLC - investment company focused on long-term returns in excess of the total return from the MSCI All Cos World index - Enters into unsecured three-year GBP30 million term loan facility agreement with Royal Bank of Scotland International Ltd, intended to be fully drawn. Loan will represent approximately 10% of company's net asset value once drawn. Appoints Martin Currie Fund Management Ltd as alternative investment fund manager, having "decided that it is now in the best interests of the company that it has a modest level of structural gearing consistent with the gearing policy".

----------

IQ-AI Ltd - medical software company with headquarters in Jersey - Notes that its Liver Surface Nodularity software application is now CE Mark approved. LSN algorithms process CT images of livers to assess nodules on the surface, conducting a virtual biopsy. This confirms that the LSN meets essential requirements of the European Medical Devices Directive. Follows US Food & Drug Administration's granting of 510(k) market clearance for LSN software earlier in November. IQ-AI says: "These recent regulatory milestones permit IQ-AI's subsidiary, Imaging Biometrics, LLC, the manufacturer of record for LSN, to market and sell the software to the world's two most prominent healthcare markets."

----------

Braemar Shipping Services PLC - London-based provider of technical expertise and professional marine and energy services - Says AqualisBraemar ASA will acquire LOC Group. Baemar Shipping holds an approximately 27% stake in AqualisBraemar, which is an associate company. Combination is intended to create "leading global independent offshore energy and marine consultancy". "Braemar believes this expansion will help generate further momentum for AQB, building on the strong progress stated in its Q3-2020 results, and has therefore shown its support and given the AQB board undertakings to vote in favour of the transaction." Braemar Shipping to hold around 21% stake in enlarged group.

----------

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
23 Oct 2019 09:32

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

Read more
2 Oct 2019 15:15

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

Read more
21 Aug 2019 11:49

ReNeuron boosts scientific advisory board with three appointments

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the appointment of professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its scientific advisory board on Wednesday.

Read more
14 Aug 2019 15:35

ReNeuron's New Cardiff University Venture Gets Research Grant

(Alliance News) - ReNeuron Group PLC on Wednesday said a new venture with Cardiff University has secured a UK government grant to research and develop new treatments for hard-to-target disorders a

Read more
14 Aug 2019 11:16

ReNeuron enters grant-funded partnership with University of Cardiff

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group is partnering with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform, it announced on Wednesday.

Read more
16 Jul 2019 12:16

ReNeuron Secures Patents For Its Exosome Technology Platform

(Alliance News) - ReNeuron Group PLC on Tuesday said it has expanded its intellectual property estate via the grant of patents, covering its exosome technology platform.The cell-based said

Read more
11 Jul 2019 11:36

ReNeuron Annual Loss Narrows On Finance Income And Licence Fee

(Alliance News) - ReNeuron Group PLC on Thursday said its loss narrowed in its most recent financial year after it received an exclusivity fee and increased finance income.Shares in were at

Read more
14 Jun 2019 15:49

ReNeuron wins 'Breakthrough of the Year' at European Mediscience Awards

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards, it announced on Friday.

Read more
8 May 2019 11:19

ReNeuron Expects Annual Results In Line With Views After Progress

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday said it expects its annual results to be in line with the board's expectations as it made progress on several clinical cell-based also

Read more
8 May 2019 08:53

ReNeuron advances blindness and stroke therapy candidates

(Sharecast News) - Therapeutics outfit ReNeuron continued to trade in line with expectations throughout its recently wrapped up trading year, advancing both its human retinal progenitor cell therapy candidate and its CTX cell therapy candidate.

Read more
26 Apr 2019 12:09

ReNeuron upbeat on early data from retinitis pigmentosa trials

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced updated positive preliminary data in its ongoing phase 1 and 2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP), on Friday.

Read more
26 Apr 2019 09:58

ReNeuron Reports Positive Test Results For Blindness Treatment Therapy

LONDON (Alliance News) - ReNeuron Group PLC on Friday reported positive trial results for its human retinal progenitor cell therapy candidate for treating blindness-causing disease retinitis in up

Read more
11 Apr 2019 18:24

DIRECTOR DEALINGS: ReNeuron Chair And Other Board Members Buy Shares

LONDON (Alliance News) - ReNeuron Group PLC said a number of directors purchased shares on Thursday, including Non-Executive Chair John Berriman who bought 80,000 shares at 225 pence Thursday, in

Read more
9 Apr 2019 10:55

ReNeuron Signs Licence Deal For CTX, hRPC Cell Programmes In China

LONDON (Alliance News) - ReNeuron Group PLC on Tuesday said it has signed an exclusive licence agreement for the development, manufacture and commercialisation of its CTX and hRPC cell therapy in

Read more
4 Apr 2019 14:19

ReNeuron upbeat on progress in hRPC study

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.